188 related articles for article (PubMed ID: 34533824)
41. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
Yang M; Elmuti L; Badawy SM
Biomed Res Int; 2022; 2022():2122056. PubMed ID: 35898672
[TBL] [Abstract][Full Text] [Related]
42. An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.
Mnika K; Pule GD; Dandara C; Wonkam A
OMICS; 2016 Oct; 20(10):565-574. PubMed ID: 27636225
[TBL] [Abstract][Full Text] [Related]
43. Inpatient use of laxatives during opioid administration in children with sickle cell disease.
O'Brien SH; Fan L; Kelleher KJ
Pediatr Blood Cancer; 2010 Apr; 54(4):559-62. PubMed ID: 20049931
[TBL] [Abstract][Full Text] [Related]
44. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
45. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
46. Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease.
Fogarty H; Gaul A; Syed S; Aleksejenko N; Geoghegan R; Conroy H; Crampton E; Ngwenya N; Tuohy E; McMahon C
Ir J Med Sci; 2022 Apr; 191(2):809-816. PubMed ID: 33745105
[TBL] [Abstract][Full Text] [Related]
47. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
Lanzkron S; Haywood C; Hassell KL; Rand C
J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
[TBL] [Abstract][Full Text] [Related]
48. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
49. Communication about opioid versus nonopioid analgesics in the emergency department.
McCarthy DM; Cameron KA; Courtney DM; Adams JG; Engel KG
J Opioid Manag; 2015; 11(3):229-36. PubMed ID: 25985807
[TBL] [Abstract][Full Text] [Related]
50. Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse.
Smith WR; McClish DK; Roberts JD; Kandalaft O; Dahman B; Knisely J; Levenson J; Roseff S; Aisiku IP
J Opioid Manag; 2019; 15(4):323-331. PubMed ID: 31637684
[TBL] [Abstract][Full Text] [Related]
51. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of Nonopioid and Opioid Prescriptions Among Commercially Insured Patients with Chronic Pain.
Miller GF; Guy GP; Zhang K; Mikosz CA; Xu L
Pain Med; 2019 Oct; 20(10):1948-1954. PubMed ID: 30481359
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive, integrative management of pain for patients with sickle-cell disease.
Yoon SL; Black S
J Altern Complement Med; 2006 Dec; 12(10):995-1001. PubMed ID: 17212571
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
55. Pain in sickle cell disease: current and potential translational therapies.
Sagi V; Mittal A; Tran H; Gupta K
Transl Res; 2021 Aug; 234():141-158. PubMed ID: 33711512
[TBL] [Abstract][Full Text] [Related]
56. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
Harris KM; Preiss L; Varughese T; Bauer A; Calhoun CL; Treadwell M; Masese R; Hankins JS; Hussain FA; Glassberg J; Melvin CL; Gibson R; King AA;
JAMA Netw Open; 2023 May; 6(5):e2314070. PubMed ID: 37200033
[TBL] [Abstract][Full Text] [Related]
57. Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
Mvalo T; Topazian HM; Kamthunzi P; Chen JS; Kambalame I; Mafunga P; Mumba N; Chiume M; Paseli K; Tegha G; Kumwenda W; Heimlich JB; Ellis G; Key N; Gopal S; Hoffman I; Ataga KI; Westmoreland KD
Pediatr Blood Cancer; 2019 Nov; 66(11):e27954. PubMed ID: 31397075
[TBL] [Abstract][Full Text] [Related]
58. Daily pain in adults with sickle cell disease-a different perspective.
van Tuijn CF; Sins JW; Fijnvandraat K; Biemond BJ
Am J Hematol; 2017 Feb; 92(2):179-186. PubMed ID: 27880985
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.
Ibiloye EA; Barner JC; Lawson KA; Rascati KL; Evoy KE; Peckham AM
Clin Drug Investig; 2021 Mar; 41(3):245-253. PubMed ID: 33580482
[TBL] [Abstract][Full Text] [Related]
60. A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina.
Masese RV; Crego N; Douglas C; Rains G; Bonnabeau E; DeMartino T; Shah N; Tanabe P
N C Med J; 2021; 82(5):312-320. PubMed ID: 34544765
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
